How AI Is transforming regulatory submission in pharma

Behind every new medicine on the market are years of research, countless experiments, and rigorous clinical trials. Yet before it can reach the patients, it must pass through a strict testing stage known as regulatory submission. Preparing the evidence, authoring hundreds of pages of documentation, and coordinating reviews across functions and regions remains one of the most resource-intensive parts of drug development. 

AI is changing the speed and scale of the work. Leading pharmaceutical companies are applying AI across regulatory workflows to support document authoring, evidence review, submission planning, and post-market activities, with the goal of reducing timelines without compromising quality.

The regulatory landscape is evolving just as quickly. The joint FDA–EMA framework for AI in drug development, the EU AI Act, and ongoing ICH harmonisation efforts are giving the industry a clearer picture of what responsible AI adoption should look like across major markets

For regulatory affairs teams, medical writers, and compliance leaders, this is more than a technology trend. It is reshaping how regulatory submissions are prepared, reviewed, and maintained. In this article, we explore where AI is already delivering measurable value in regulatory submissions in pharma, what current regulatory expectations require, and how organisations can adopt AI responsibly while preparing for a more harmonised global landscape.

Where is AI delivering value in regulatory submissions today? 

Medical writing and clinical study reports

Medical writing has emerged as one of the first regulatory functions where AI has delivered measurable value at scale. Unlike many use cases that remain in pilot phases, AI-assisted document authoring has already become part of production workflows across leading pharmaceutical companies.

The greatest impact has been seen in clinical study reports (CSRs). These highly structured documents require authors to consolidate large volumes of clinical data, statistical outputs, and protocol information into a scientifically coherent narrative, a process that has traditionally taken weeks or months.

Today, AI can automate much of the repetitive work involved in drafting these reports. It extracts relevant information from source documents, assembles structured sections, and generates an initial draft that serves as a starting point for expert review.

At Visium, this approach has reduced the time required to produce a first CSR draft from hours to as little as 10 minutes. Across client implementations, organizations have reported a 30–70% reduction in authoring time and lead-time savings of two to seven weeks, accelerating document delivery without changing the scientific review process.

Importantly, these gains do not remove the need for medical writers. Instead, they shift their role toward the activities that require human expertise: evaluating clinical relevance, interpreting findings, ensuring scientific consistency, and making the final regulatory judgement. This division of responsibilities closely aligns with the direction outlined by both the FDA and EMA, which emphasize that AI may support document preparation while accountability remains with qualified experts.

The same operating model is now expanding beyond CSRs into other regulatory documents, including integrated summaries, clinical overviews, safety narratives, labeling, and clinical pharmacology reports, making medical writing one of the clearest examples of AI delivering practical value across the regulatory submission process.

Dossier assembly, eCTD, and regulatory intelligence

Once the documents are written, the next challenge is assembling a complete, submission-ready dossier. Here, AI is reducing much of the manual work involved in preparing regulatory submissions. Natural language processing tools can automatically tag content, populate metadata, verify cross-references, and check eCTD formatting requirements, turning quality control from a final checkpoint into a continuous process throughout dossier preparation.

AI is also proving valuable in regulatory intelligence. It can rapidly scan global guidance, identify the requirements that apply to a specific submission, and highlight differences across markets. While regulatory agencies are moving toward greater alignment on AI governance, important regional variations remain. Identifying those differences early helps teams avoid costly revisions later in the submission process.

Pharmacovigilance and post-market safety

Some of the most mature AI use cases in the regulatory lifecycle appear after approval, where companies must continuously monitor product safety in the real world. Pharmacovigilance is a natural fit for AI because adverse-event signals are often buried across large volumes of structured and unstructured data, from safety databases to patient-generated content on social media.

We helped one of the leading pharmaceutical companies use LLMs  to strengthen adverse-event monitoring across social media data. The challenge was not only scale, but reliability: the existing model struggled when moving from training to production, where language patterns and data distributions changed. By building an ML pipeline that monitored and adjusted for these shifts, we demonstrated a more reliable approach to adverse-event detection and created a transparent, compliant workflow for patient safety experts.

AI creates regulatory value in the post-market setting, by helping pharmacovigilance teams validate signals faster, and document decisions. The same logic extends into adjacent post-approval workflows, including HTA and reimbursement strategy, where AI can turn historical committee decisions and negotiation transcripts into structured intelligence for evidence-based decision-making.

What does responsible AI implementation require? 

Accelerating the process and improving speed create value only if it can withstand regulatory scrutiny. For AI used in regulatory submission workflows, both FDA and EMA expect implementation to sit within the quality management system and to follow the same validation discipline applied to other regulated software. The starting point is a clearly defined context of use, including the approved inputs, outputs, workflows, and decision boundaries for the tool. When the scope changes, validation needs to be revisited to confirm the tool remains fit for purpose across the relevant markets. 

This also makes monitoring an ongoing part of responsible deployment. EMA guidance highlights the need to track model performance as the underlying data changes, since outputs can shift when real-world inputs evolve. In practice, this means AI systems used in regulatory workflows need more than a launch validation. They need performance monitoring, audit trails, version control, and clear traceability from each generated output back to the model version and source data used to produce it. These controls are becoming central to moving AI from experimentation into submission-ready workflows.

Grounding generated outputs in trusted source data

While hallucinations are  a concern, the practical response is to design AI systems around controlled generation. In regulatory writing, this means starting from approved templates, connecting the model to validated internal and external source data, and defining exactly how outputs move through the workflow before they reach submission teams. In Visium’s approach, AI-generated drafts are reviewed by domain experts, while dedicated review agents check the document for consistency and compliance. Each action is logged and traceable, with role-based controls, GxP validation support, audit trails, and human sign-off built into the workflow.

Hallucination risk cannot be eliminated, but it can be reduced, surfaced, and controlled through the way the system is designed.The system does not rely on open-ended generation alone. It operates within the sponsor’s data environment, uses the company’s templates and institutional knowledge, and keeps experts accountable for review and approval. For regulatory submissions, that combination of source grounding, controlled workflows, and traceability is what makes AI-generated documents easier to review, easier to defend, and safer to scale.

Getting the sequencing right

AI in regulatory submissions does not require a perfect starting point. The strongest first use cases are the ones where structure can be introduced around a clear, bounded workflow, such as CTD summary modules, reference-document synthesis, labeling gap analysis, and structured content reuse. These areas are practical starting points because they help teams organise fragmented source material, standardise outputs, and build validation discipline as they go.

From there, scale depends on three foundations: clean regulatory data, validated workflows, and trained teams. Structured content, controlled terminology, metadata quality, and modern RIMS are what allow AI tools to perform consistently across submission work. Governance should define context of use, review ownership, audit trails, revalidation triggers, and market-specific requirements before use cases expand across regions.

For regulatory leaders, the priority is to prove AI value in controlled workflows, build the validation evidence, and create a governance model that can scale safely.

If your team is ready to move from AI pilots to submission-ready workflows, Visium can help you define the right use cases, design the validation approach, and implement AI systems built for regulated environments.